Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Game On: Medicare Will Parry Manufacturer Efforts To Sidestep Price Negotiation, Guidance Says

Executive Summary

CMS will need to continue to be ‘savvy’ to strategies brand manufacturers already employ to shape the landscape for generic and biosimilar competition, policy expert says.

You may also be interested in...

PhRMA’s Opening Gambit: Limiting Medicare Price Setting To The IRA's Minimum Discount

CMS should adopt the minimum price reductions under the Inflation Reduction Act for most selected drugs in the early years of the Medicare price negotiation program, PhRMA urges and recommends the agency should retain that approach in the long-term for younger drugs, those targeting an unmet medical need or those representing therapeutic advances.

Medicare Price Negotiation And A New Twist On Product Hopping

Tactic generally used to foil generic or biosimilar competition may find a new use in combination with such competition to avoid price negotiation, legal experts observe.

A Level Playing Field? Medicare Tries To Balance Transparency, Confidentiality With Drug Price Negotiations

Drug manufacturers may want more ability to communicate about their drug price negotiation experience with Medicare than CMS is proposing, but if that jeopardizes protections for proprietary information, it may not be worthwhile.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts